FDA Panel Votes Against Capricor's Duchenne Heart Disease Therapy

An FDA panel has voted against Capricor's proposed therapy for Duchenne heart disease, delivering a setback to the company's efforts to bring the treatment to market. The decision impacts the future of the therapy.